Introducing the Portuguese Society of Dermatology and Venereology What we're missing out on! > A new membership category for nurses For medical assistants too >
News The leading European professional organisation for Dermatology and Venereology
Welcome to the Spring Symposium 2021 6–7 May 2021 >
Already registered? 16 th EADV Spring Symposium 6–8 May 2021
Reflections on EADV and the post‑pandemic era
media and by holding a vibrant series of up-to-date webinars and online courses. Empowered by the expertise and solidarity of our members, EADV is committed to cultivating a sense of community and continuing to provide the means for members to be more engaged in our work. The pandemic has also had a profound effect on certain long-awaited changes, such as digital learning and telemedicine. We may all feel a sense of “Zoom” fatigue at some point, but at EADV we recognise that online activities have kept us together at times of great uncertainty. The success of our Virtual Congress last year, the overwhelming attendance at EADV online courses and the encouraging prospect of our 2021 scientific events show the seminal role that online learning will have in complementing our educational events and in reaching wider audiences in the future. In planning a broad range of EADV activities for the coming years (fellowships, scholarships and courses), we are revitalising our >
draw together the dermato-venereology community in Europe, and further afield. During the pandemic, we systematically sought to support members by providing expert recommendations, maintaining regular communication through social “ What we call the beginning is often the end. And to make an end is to make a beginning. The end is where we start from .” T. S. Eliot
The COVID-19 pandemic was official- ly announced just over a year ago and marked the beginning of an unprec- edented health crisis. Many countries are currently experiencing a “third wave” while simultaneously implementing a population-wide programme of vaccina- tions. It is helpful to reflect on some of the lessons we have learnt as we make our plans going forward. As healthcare providers, dermatologists have faced innumerable difficulties both on professional and personal levels. Delivering optimal care throughout the pandemic has been one of their main challenges. EADV is in a unique position to
“ We aim to become leading providers of e-learning in dermato- venereology by employing innovative, broadly accessible courses and delivering state-of-the-art education. ”
The lessons we have learnt during this pandemic have come at a great human and societal cost. It is hard to predict which changes will be sustained in the post-pandemic world. I am, however, confident that this will be a new era of growth for EADV. With a mindset of learning and discovery, we have the opportunity to enhance the position of our speciality in the rapidly evolving healthcare landscape and to prepare and guide our members for forthcoming changes. I wish you a wonderful and “liberating” spring time and look forward to greeting you at the Virtual Spring Symposium! l
educational programme to offer complete coverage of the dermato- venereology curriculum. We aim to become leading providers of e-learning in dermato-venereology by employing innovative, broadly accessible courses and delivering state-of-the-art education. As we gradually enter the post- pandemic era, public health will be at the top of the EU policy agenda. The digitalisation of healthcare services, preventive medicine and equal access to care will be high priorities. EADV will have a firm presence in the public health field to help raise awareness on skin and venereal diseases and improve dermatological care. Advocating for skin cancer and melanoma and creating funding opportunities for research on cutaneous disease are our immediate goals. As digital technology transforms healthcare, we also need to reinforce the role of our specialty in integrating innovative modalities, such as teledermatology and artificial intelligence (AI), into a new and effective model of care and patient-physician engagement. And as we, as physicians and patient advocates, cultivate this new culture, we need to practice locally, act Europeanly and think globally. EADV is committed to broaden our collaboration with national and international dermatological societies, patient organisations and other stakeholders. Combining our views and perspectives can create synergies and help shape the future of dermatological care. >
Prof Alexander Stratigos
Alexander J. Stratigos EADV President (2020-2022)
Editorial WINTER 2015–2016 78 SPRING 202
Prof Christos Zouboulis
A special spring this year
Spring is a very special season. It wakes us up and fills us with positive, vivid feelings, and it provides energy for an active life . Italian composer Antonio Vivaldi dedicated a long part of his illustrious “ Four Seasons (Le quattro Stagioni) ” – first presented in 1725 with the title “ The risk of harmony and invention (Il cimento dell’armonia e dell’inventione) - to spring. Its allegro, which translates as tipsy, lively, funny, cheerful, happy, exuberant, jolly, dictates the speed for the orchestra. In spring, butterflies, beautiful creatures of change, bud into being after having accumulated enough energy as a caterpillar. In spring, the world smells reborn, leaves sprout from where they have been hibernating in the brittle branches of trees and bushes. In spring, the world is created once more from scratch, the botanic world at least. For humans, spring prompts greater productivity – in every sense. This edition of EADV News is in keeping with our dream to illustrate the wealth of our scientific dermato- venereology field combined with a little bit of healthy jealousy for our older sister, the Journal of the European Academy of Dermatology and Venereology , which is doing so well thanks to its editor Prof Johannes Ring. Full of spring intentions, this issue aims to provide an answer to the eternal question: Is dermato-
venereology a “small” medical specialty or not? EADV News is proud to hand the word over to the authors featured in this edition. Among others, Prof Claus Garbe summarises the fascinating world of new drugs in dermato- oncology, Prof Kristiina Aalto-Korte updates our knowledge of contact allergies and allergology, Dr Catherine van Montfrans teaches us the importance of tactile care and how it can be maximised through skin- on-skin touch, Dr Samantha Anne Vaughan Jones reports on the activities of the EADV Pregnancy Task Force and Prof Angelo Marzano and Prof Marco de Andrea – taking a dermato- immunology point of view - enrich our understanding of the current status of COVID-19 vaccinations and the vaccines already developed. The contribution of the President of the Portuguese Society of Dermatology and Venereology Dr António Massa on the “Would-be 2021 Spring EADV Symposium in Porto” reveals another aspect of our spring dreams; the anticipation of the end of scientific isolation. EADV News continues to present the various faces of our specialty and the activities of dedicated subspecialty organisations in order to inform young dermatologists about “their” specialty and to provide evidence of the great
In this issue
Advances in dermatological oncology________4
Inviting nurses and medical assistants to join EADV ____________________________________ 6
COVID-19 vaccines _____________________________ 8
COVID-19 survey ______________________________ 10
Introducing the Portuguese Society of Dermatology and Venereology _ _____________ 12
Increases in allergology ______________________ 14
New task force bylaws _________________________ 16
Skin Diseases in Pregnancy Task Force _ ____ 18
The Dermatology Podcast ___________________ 20
The power of touch ___________________________ 22
Join us at the EADV Spring Symposium 2021 _____________________________ 24
Obituary: Prof Hiroshi Shimizu ______________ 27
Calendar of Events ____________________________ 28
spectrum of European dermatology. This is just one of the important reasons to continue being or to become a member of the European Academy of Dermatology and Venereology and to follow our activities during our regular scientific events, such as
the upcoming virtual Spring Symposium 2021. It is up to us as human beings to let the world grow in our hearts and as dermatologists and venereologists to continue advancing our specialty. We can find new points of interest and anchors within our daily work, especially when familiar, routine activities seem to break away, as has happened during the COVID-19 pandemic. Let us open ourselves to the continuous education offered in the large world of dermato- venereology. Our specialty will enrich our minds with the beauty and fulfilment of new knowledge. Let us radiate into our dermato-venereology world with a positive spirit and we will be rewarded with happiness in our daily work. This is a special spring editorial that describes my strong wish to awaken life once more, filling us with hope for a better future. l
T There have been major changes in dermato-oncology over the past decade , primarily due to the approval of many new drugs (summarised in Table 1). In addition, surgical treatments have also evolved. For example, the indication for excision of melanoma with a small safety margin and the indication for sentinel lymph node biopsy have not changed compared with previous decades, but complete lymphadenectomy is no longer performed for positive sentinel lymph node biopsy because two large, randomised trials have shown no effect on survival.
Prof Claus Garbe
“ Tremendous progress has been made with the introduction of new drugs in dermato- oncology ”
Targeted therapies are available for BRAF mutant melanoma (45%), each combining a BRAF inhibitor and a MEK inhibitor. Three such combinations are approved and can be used in metastatic patients. The combination of dabrafenib and trametinib is also approved as adjuvant therapy in stage III. The greatest advancement in the treatment of metastatic and advanced melanoma, squamous cell carcinoma and Merkel cell carcinoma has been the development of immune checkpoint inhibition (ICI). In melanoma, combined ICI therapy with the CTLA-4 antagonist ipilimumab and the PD-1 antagonist nivolumab for four cycles is now common, followed by maintenance therapy with nivolumab alone. Pembrolizumab is another drug approved for melanoma. For advanced and metastatic squamous cell carcinoma (head/neck), cemiplimab can be used, along with pembrolizumab and nivolumab. Specifically for Merkel cell carcinoma, the PD-L1 antagonist
Christos C. Zouboulis MD PhD Editor
Advances in dermato-oncology
While five-year survival rates for stage IV metastatic melanoma were less than five percent in the previous decade, they have now risen to over 50% in trials. This figure illustrates the tremendous progress that has been made with the introduction of new drugs in dermato- oncology. l Claus Garbe , MD Professor of Dermatology President of the European Association of Dermato Oncology (EADO)
avelumab has been developed. Talimogene laherparepvec (T-Vec) is approved for the treatment of melanoma. It is an oncolytic herpesvirus construct and is applied intratumorally to elicit an immune response. Leaps forward have also been made in the adjuvant therapyofmelanoma. Previously, only interferon-alpha was available for adjuvant treatment. The impact of interferon-alpha was comparatively low (hazard ratio ~ 0.85), with some side effects resulting in a reduction in quality of life. Meanwhile, in stage III melanoma, the checkpoint inhibitors nivolumab and pembrolizumab have been approved
for adjuvant treatment. Here, a notable impact on progression-free and overall survival has been reported, with a hazard ratio ~ 0.50. In addition, adjuvant use of the combination of the targeted drugs dabrafenib and trametinib results in a hazard ratio ~ 0.50. In other words, the risk of recurrence and the risk of death are reduced by 50%. There are hardly any other tumours for which such effective adjuvant therapies are available. Adjuvant therapy is now being tested in large trials in stage II patients with thick primary tumours. There is a strong likelihood that further approvals will be forthcoming in this area.
Table 1: New drugs for the treatment of advanced skin tumours
Inviting nurses and medical assistants to join EADV
N Nurses play an important role in daily dermatology practice . The idea of involving nurses in EADV as members and as participants at congresses has been around for a long time. However, the creation of a membership category for nurses had to be put on hold as no common definition of “nurses” could be found in Europe.
New membership category ten years in the making
(CPD) and continuingmedical education (CME) of nurses with specific interest in dermato-venereology. Promote EADV as a major educational provider for related healthcare professionals 3 Assess how to collaborate with European and national nurse associations to reinforce partnerships and advocacy directed toward policy makers 4 Improve knowledge and insights into the roles and responsibilities of nurses in the management of patients in Europe in order to identify needs and issues Finally, in 2020, with the help of the EADV Statutes and Development Committee, a new membership category was created.
In 2016, the EADV’s Executive Committee initiated a Nurse Association Working Group (NAWG) with the aim to: 1 Develop initiatives to increase the presence of nurses in the EADV landscape 2 Implement dedicated sessions for the continuing professional development
Nurse and medical assistant members
Definition as per EADV statutes
Documentation to provide
The application has to be accompanied by the endorsement of an EADV Fellow member in good standing.
• This category of membership is open to licensed practical, registered or practitioner nurses and medical assistants involved in the nursing care of dermato- venereology patients. • Nurse and medical assistant members shall be entitled to vote, but are not eligible to be elected to the Board or as officers of the Academy.
1 The online membership application form 2 Confirmation of professional status: • A copy of the applicant’s current medical license/diploma OR • Official letter (in English) from a dermatological nursing society 3 Agreement of adherence to EADV statutes
Discover the benefits of EADV membership or contact us .
network, partner and strengthen synergies. Our growing network would like to see a minimum of one nurse representative for each European country at meetings in general who would act as a liaison with local nurses. Survey The NAWG created a survey. pg10 to identify the profile and needs of non- dermatologist healthcare practitioners. The results clearly showed the current competences of nurses and the the training areas EADV could help cover. Nurse curriculum NAWG is preparing a curriculum for nurses interested in dermato-venereology to help develop a common training framework which will lead to the recognition of dermatology specialist nurses. Nurses are kindly invited to join the EADV nurse family and contribute actively to help us achieve our objectives. l Christa De Cyuper Chair of the EADV Nurse Association Working Group (NAWG) Any questions or comments can be sent to the NAWG coordinator marina. email@example.com .
Dr Christa De Cuyper, chair of NAWG
What has NAWG done so far? What are its plans for the future? Education Since 2012, an annual nurse session has been held at each EADVCongress. This was converted by NAWG into a “Nurse Day”, a dedicated full-day track that comprises lectures by nurses and physicians on topics of common interest. The first Nurse Day took place during the 2019 EADV Congress in Madrid, Spain. It featured an attractive programme on hand dermatitis and wound healing, including interactive workshops with a balanced faculty of doctors and nurses. The second Nurse Day, during the 2020 Virtual Congress, was dedicated to the International Year of the Nurse and the Midwife. It was very well I stated my career in 1987 and stumbled across dermatology in 1994, a time when dermatology nurses were as rare as ‘hens teeth’ and specific nurse training even more elusive. Carving out a career in this wonderful speciality required determination and perseverance. I finally managed to land a dermatology nurse position in October 2000. Nearly three years later, I was introduced to the vast educational resource that is EADV at the conference in Barcelona, Spain. My mind was blown. The level of education I received rocked my world. I was able to attend the same lectures as my medical colleagues, which up until then had been a closed world to me. I could hear about Meet Annette Aldridge, EADV’s very first nurse and medical assistant member
attended. A third Nurse Day is scheduled to take place on 1 October 2021. It will focus on genital dermatoses, the burden of skin diseases and mental health. Going forward, training courses for nurses will be offered in cooperation with the EADV School. Nurses in key roles and nurse teachers will be involved in these activities. The first training course for nurses will take place from 25–27 November 2021 in Malaga, Spain, if COVID-19 permits. Networking During EADV congresses, NAWG and the PWG (Patient AssociationWorkingGroup) also organised a meeting that brings together nurses and patient associations. Attendees value the opportunity to the latest research and join in panel discussions. And I was encouraged to develop my skills and knowledge. I came back to the UK inspired to share what I’d learned, help improve patient care and instigate new practices. The conference was the ignition I needed to dream of gaining an MSc in Dermatology. As soon as the University of Hertfordshire, UK, created the course, I enrolled, and I achieved a university prize in the process. Since Barcelona, I have been to many conferences, including the World Congress in 2007, but I always come back to EADV for quality content. EADV is forward thinking and proactive, as demonstrated by the superb virtual conference in October 2020 that offered participants extended access to content even after the conference had finished -
long may this function continue, especially for those who have difficulty travelling to other countries. What an amazing resource and the motivator
I needed to become an EADV member. EADV is supportive and inclusive, and now that I am a member I have the additional benefit of access to a plethora of journals, publications, training, events and patient information relevant to my practice all in one place. I am proud to be the first nurse to become an EADV member and I encourage all my colleagues who have a thirst for knowledge and a passion for dermatology to join me. l
Annette Aldridge MSc, PGCE, RGN
COVID-19 vaccines: A rapid response to the pandemic
O Over the past year of a dramatic pandemic, we have seen an exciting and unprecedented race to find a promising vaccine against SARS-CoV-2 infection. Traditional vaccine development can take up to 20 years, starting with a lengthy discovery phase for vaccine design, followed by exploratory preclinical experiments. This in turn is followed by a phase of more severe preclinical experiments and toxicology studies, which, if successful, lead to production. Simultaneously, an investigational ‘new drug application’ is filed and the potential vaccine moves on to phase I, II and, hopefully, III trials. When phase III is completed and the predetermined objectives have been achieved, a ‘biologics license application’ is filed. The vaccine is then reviewed by regulatory agencies before its final approval. Only once it has been approved can large-scale production begin.
Prof Angelo Valerio Marzano
development for SARS-CoV-2 could sidestep the discovery phase, resulting in an accelerated timeline. Indeed, phase I/II trials were able to begin earlier thanks to the adoption of existing processes. Due to the overall emergency of the situation, phase III trials began after the interim analysis of phase I/II results, with several clinical trial steps running in parallel. At the same time, vaccine manufacturers have started a risky large-scale production of promising vaccine candidates. Based on this accelerated pathway, some vaccine candidates have been licensed through an initial emergency use authorisation, others are about to be approved and others still remain in the evaluation phase (see Table 1 for reference at time of writing (March 2021)). Taking a novel approach Contrary to the above, approved vaccines and those pending approval have been designed following different approaches. Interestingly, two of the first to be approved - and used with brilliant results (namely BNT162b2/COMIRNATY – Pfizer and mRNA-1273 – Moderna) - are mRNA- based with a relatively recent development procedure. In these cases, previous pre- clinical experience with Zika virus and cytomegalovirus has been very informative, with the clear advantage that the vaccine can be produced completely in vitro. Others, including AZD1222 – AstraZeneca and Ad26.COV2.S – Janssen, are based on a recombinant adenoviral vector encoding the S antigen of SARS-CoV-2. Similarly, Sputnik V - The Gamaleya National Center relies on a human adenoviral vector and is currently being considered
Prof Marco De Andrea
Calling on what we already know Based on previous experience from SARS-CoV and MERS-CoV, vaccine
and a technical point of view, to be exploited in the event of a new pandemic emergency. l
for approval by the European Medicines Agency (EMA). Finally, Sinopharm and Sinovac are pursuing a vaccine strategy that covers a ‘more classical’ inactivated virus produced in Vero cells. All in all, this unprecedented process of developing vaccines as a countermeasure against SARS-CoV-2 should be regarded as an opportunity, both from a legislative
Transplantation, Università degli Studi di Milano, Milan, Italy 3 Viral Pathogenesis Unit, Department of Public Health and Paediatric Sciences, University of Turin – Medical School, Turin, Italy 4 CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
Angelo Valerio Marzano , MD 1,2 ; Marco De Andrea , MD, PhD 3,4
1 Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 2 Department of Pathophysiology and
Status of COVID-19 vaccines (according to WHO Guidance Document, 23 March 2021)
Recombinant ChAdOx1 AdV vector encoding the SARS- CoV-2 Spike protein Recombinant, replication- incompetent Ad26 vectored vaccine encoding the SARS- CoV-2 Spike protein
SK BIO - AstraZeneca
15 February 2021
Serum Institute of India DCGI
15 February 2021
Adenoviral vector based
12 March 2021
Clinical and CMC review ongoing Additional data expected.
Will be determined when all data is submitted
Additional information submitted
Human Adenovirus Vector- based COVID-19 vaccine
The Gamaleya National Center
Earliest April 2021
Sinopharm BIPB 4
Inactivated, produced in Vero cells
Earliest April 2021
Not yet assessed
Recombinant Novel Coronavirus Vaccine (AdV Type 5 Vector)
Vector State Research Centre of Viralogy and Biotechnology
Letter received not EOI. Reply sent on 15 January 2021 Response to 2 nd EOI sent 29 January 2021. Additional information requested.
Recombinant Novel Coronavirus Vaccine (CHO Cell)
Recombinant protein subunit produced in CHO cells
Zhifei Longcom, China
Inactivated, produced in Vero cells
Inactivated, produced in Vero cells
Bharat Biotech, India
Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein
1 Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made 2 Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors’ questions are submited 3 NA: not applicable
4 Beijing Bio-Institute of Biological Products Co-Ltd, China 5 Wuhan Institute of Biological Products Co Ltd, China
COVID-19 survey Why dermatologists should be prioritised for vaccination
Prof Rolf Astendorf
A recent survey by German television channel WDR-Auswertung (see graphic) demonstrates that despite strict precautions undertaken in medical settings, the risk of COVID‑19 transmission in these environments remains high. The survey’s findings are supported by other similar inquiries. The impact for dermatologists who often undertake lengthy surgical procedures however has not been sufficiently covered by the research. A quick poll of the EADV Board and members of the Office Management Task Force shows there are two main concerns: There is no vaccination programme at all in Ukraine and Montenegro and dermatologists are not prioritised early enough or at all in a number of other countries, namely e.g. Belgium, Finland,
Germany, Norway and Switzerland. As Dr Mihaela Leventer’s experience shows, this is an issue that needs to be urgently addressed. Apersonalviewoftheimportance of vaccination “On 1 February 2021, we finished vaccinating all staff at our clinic in Bucharest, Romania, but continued to respect COVID-19 safety measures, operating only on patients who could provide a negative PCR test result. Untested patients were accepted solely for consultations and aesthetic treatments. As a rule, I always wear two masks, both in the clinic and outside. Two weeks after my second dose of the Pfizer vaccine, I developed 1,000 IU of anti-spike antibodies. Despite all this,
six weeks after my second shot I tested PCR positive. I suddenly developed a high fever, had chills and suffered intense fatigue. It was revealed that I had been infected with the UK strain of COVID‑19. What had seemed so incredible had become possible! National statistics show that Romania is in its third wave of the pandemic. Bucharest is (at time of writing) nearing six cases per 1,000 people. Out of 700,000 vaccinated people, I am among the 1,000 who developed COVID‑19. While it turns out that vaccination doesn’t provide immunity, it does ease the effects of the virus. Within three days, my fever had dropped from 39°C to 37°C and then my symptoms disappeared. My PCR test became negative after five days. None of the other staff at the clinic had positive PCR results, however my vaccinated husband did become positive, albeit without any symptoms of the virus. My case shows that you should never lower your guard despite the fact that you have been vaccinated. To avoid the worst, please make sure you are vaccinated.” l Dr Mihaela Leventer Bucharest, Romania Dr Rolf Ostendorf Dermatologist-Allergologist-Phlebologist Vice-chairman Landesverband Nordrhein Berufsverband der deutschen Dermatologen e.V.
Investigating sources of COVID-19 infection in North Rhine-Westphalia, Germany
Where are people infected?
6.6% 6.2% 5.1% 1.2% 1.0%
Source : Survey by WDR-Auswertung of local health authorities in North Rhine-Westphalia, Germany, between 1- 14 February 2021
EADV European Academy of Dermatology and Venereology
Become a part of the largest pan-European community of dermatologists and venereologists in Europe. Engage , learn and share with other practitioners, experts and specialists. Join our EADV Community
Membership benefits EADV members have exclusive access to the following:
Presentations and webcasts from past EADV scientific meetings.
Priority access to the EADV educational programme including EADV courses and development programmes.
Access to the EADV e-learning platform.
Journal of the European Academy of Dermatology and Venereology ( JEADV ) and new JEADV app.
Voting rights and possibility to run for office for EADV leadership positions.
Direct access to 17 medical journals and 21 textbooks.
Reduced fees for EADV scientific meetings, congresses and spring symposia.
For further information and to apply, please visit www.eadv.org or contact firstname.lastname@example.org
Introducing the Portuguese Society of Derma Would-be host of the up Symposium explains its activities… and what we’
T The Portuguese Society of Dermatology and Venereology (SPDV) was formed in 1936 and held its first scientific meeting in 1942. It currently has 454 effective, 18 aggregated, 13 correspondent and four honorary members. It fully expects to reach the 500 member mark soon and has only been delayed in this due to the pandemic, which froze new admissions. SPDV’s patron is Bernardino António Gomes (1768-1823) who is considered to be the first Portuguese dermatologist and author of the first Portuguese book on dermatology (1820). His chemical and botanical knowledge made possible the isolation of cinchonine from Cinchona officinalis, a medicinal plant, which initiated the research of alkaloids in the treatment of malaria.
groups organise periodic update sessions and collaborate actively in SPDV and international meetings. SPDV holds twomeetings a year which are well attended by both national members as well as international participants, who kindly share their experiences, namely in dermatological therapy. The presence of colleagues from Portuguese-speaking countries, like Angola, Mozambique and Cape Verde, is a particular point of attention. It has been the society’s main goal to make these meetings as practical as possible to make sure they add value to participants’ daily practice. Residents are invited to present their work in English to facilitate exchange with peers from other countries. An agreement with the neighbouring Spanish Academy of Dermatology and Venereology means greater participation of Portuguese dermatologists in Spanish meetings and vice versa . The pandemic has unfortunately impacted these meetings, but in November 2020, the society ran its first virtual congress. It plans to return to face-to-face meetings as soon as possible (potentially in July 2021), a wish broadly expressed by both dermatologists and the pharmaceutical industry. Every year, SPDV distributes scholarships, mainly to national residents, for internships in departments within Portugal or in other, mainly European, countries that commit to receive them in a very friendly and open manner. It also sponsors research projects and awards prizes for work of recognised value,
The society issues its own quarterly medical journal, which it launched in 1942. The main objective of the journal is the publication of quality, peer-reviewed research work in all fields of the specialty, namely articles of continuous medical education, original and review articles, clinical case reports and letters to the editor. SPDV also promotes the constitution of multiple study and subspecialty groups, currently in the fields of acne, atopic dermatitis, contact dermatitis, cosmetic andaestheticdermatology,dermatological surgery, dermatopathology, dermoscopy and telemedicine, investigation of sexually transmitted diseases, mycology, paediatric dermatology, photobiology, psoriasis and trichology. Many of these
tology and Venereology coming 2021 EADV Spring
history, mission and ’re missing out on !
Prof António Massa
like meeting presentations and articles published in our journal. In 1992, SPDV began sponsoring volunteer missions, bringing dermatologists and other specialties together. The last mission was in February 2020. It saw 21 doctors work together to deliver dermatological care to especially vulnerable and isolated populations, namely senior residents in rural areas of the country. Alongside skin examinations, these missions also provide some minor local surgical procedures and the referral of serious cases, like skin cancer, to larger hospitals. Outside of Portugal, these pro bono activities have also been carried out in Angola, Mozambique, Cape Verde and São Tomé and Príncipe, when possible along with the organisation of scientific sessions. Since 2003, the Portuguese Skin Cancer Association (APCC) works together with SPDV towards the prevention and early diagnosis of skin cancer via joint field campaigns in remote areas, specifically targeting sun lovers on beaches.
SPDV also facilitates the acquisition of didactic material and devices, like textbooks and
and exclusive port. The distinction of Porto as the European Best Destination and European Consumers Choice reveals its unique and strong character and unparalleled beauty. You can find out more about Porto here and here If you ever decide to visit Porto, write to SPDV and it will always have a willing colleague at your disposal to accompany or advise you. SPDV hopes to be able to receive you in Porto soon and enjoy a toast with port, along with great food and a magnificent climate. l António Massa President of Sociedade Portuguesa de Dermatologia e Venereologia (SPDV)
dermatoscopes, by members who attend SPDV meetings. Merchandise featuring the SPDV logo, like doctor coats, t-shirts and hats, is also offered to help promote skin healthcare. The 2021 EADV Spring Symposium was intended to be held in Porto, Portugal, a very friendly city that offers a rich and very affordable gastronomic experience in a safe environment, among other highlights. It is widely recognised that the Portuguese people are outstanding and friendly hosts and the inhabitants of Porto are no exception. Porto has a gorgeous cityscape with a medieval riverfront along the Douro River, extended by the Douro Valley vineyard (UNESCO World Heritage in 2001). It was the first demarcated and regulated wine-producing region in the world and is responsible for some of the best wines in the world, namely the well-known
European Society of Contact Dermatitis
why are contact
Preservatives are important causes of contact allergy. The 2010s were marked by a worldwide epidemic of methylisothiazolinone allergy due to the introduction of this preservative at high concentration levels in cosmetic products. Its use is now restricted to rinse-off products. As a result, the incidence of contact allergy has begun to decrease. However, cases caused
by occupational exposure and non- cosmetic isothiazolinone sources are on the rise and sensitisation to newer and lesser known isothiazolinones has been reported. 3 Acrylates are emerging allergens: 2-hydroxyethyl methacrylate, a monomer with numerous applications, was included in the European baseline
Prof Kristiina Aalto-Korte
Contact allergy, i.e. delayed type cell- mediatedhypersensitivity,isafascinating and absorbing field of dermatology with almost 5,000 sensitising chemicals currently known. 1 The specialty poses never-ending inspiring challenges for dermatologists who don’t fear the complicated names of organic chemicals. Allergic contact dermatitis is a purely exogenous dermatosis mediated by an immunological mechanism. In most cases, avoidance of culprit allergens leads to complete remission, which can be rewarding for the investigating dermatologist. Nickel contact allergy continues to be a problem in European Union (EU) countries, despite the EU Nickel Directive that regulates the use of nickel in jewellery and other consumer products designed to come into direct and prolonged skin contact. In a systematic review of European countries, the prevalence of nickel allergy generally remains high, affecting eight to 18% of the general population. 2
Increases in allergology; allergies becoming more prevalent?
series in 2019. Many new cases are seen due to long-lasting nail polishes. 4 Multidisciplinary collaboration between several European dermatology departments identified isobornyl acrylate , once deemed a low-risk sensitiser, as a major culprit contact allergen in glucose sensors and insulin pumps (medical devices used by diabetes patients worldwide). 5 There is a real need for EU legislation requiring the disclosure and labelling of the composition of medical devices. Lack of cooperation with the medical device industry seriously hampers the correct workup of cases of allergic contact dermatitis. 6 Among the most frequent causes of fragrance contact allergy are terpenes. Oxidised forms of fragrance terpenes limonene and linalool are already commercially available for patch testing. Recent investigations have shown that most geraniol-sensitised patients only react to the oxidised form. 7 Despite its shortcomings, the EU has the most progressive legislation in the world for preventing contact allergies. Improvements require close cooperation between dermatologist and national authorities and EU institutions. European Society of Contact Dermatitis (ESCD) organises bi-annual congresses that bring together around 400 specialists. Its official journal Contact Dermatitis has the highest impact factor (3 , 953) in the field of contact dermatitis, putting it in ninth position globally. Should you like to discover more about
contact dermatitis, we’d be happy to help. l Kristiina Aalto-Korte President, European Society of
Contact Dermatitis (ESCD) Adjunct Professor, MD, PhD
References 1. De Groot AC. Patch Testing – test concentrations and vehicles for 4900 chemicals 4 th ed.: AC de Groot Publishing; 2018. 2.Ahlstrom MG, Thyssen JP, Menne T, Johansen JD. Prevalence of nickel allergy in Europe following the EU Nickel Directive - a review. Contact Dermatitis. Oct 2017;77(4):193- 200. https://onlinelibrary.wiley.com/doi/full/10.1111/cod.12846 . 3. Herman A, Aerts O, de Montjoye L, Tromme I, Goossens A, Baeck M. Isothiazolinone derivatives and allergic contact dermatitis: a review and update. J Eur Acad Dermatol Venereol. Feb 2019;33(2):267-276. https://onlinelibrary.wiley.com/doi/ abs/10.1111/jdv.15267 . 4.Dahlin J, Berne B, Duner K, et al. Several cases of undesirable effects caused by methacrylate ultraviolet-curing nail polish for non-professional use. Contact Dermatitis. Sep 2016;75(3):151-6. https://onlinelibrary.wiley.com/doi/abs/10.1111/ cod.12608 . 5. Herman A, Aerts O, Baeck M, et al. Allergic contact dermatitis caused by isobornyl acrylate in Freestyle(R) Libre, a newly introduced glucose sensor. Contact Dermatitis. Dec 2017;77(6):367-373. https://onlinelibrary.wiley.com/doi/full/10.1111/ cod.12866 . 6.AertsO, HermanA, MowitzM, BruzeM, Goossens A. Isobornyl Acrylate. Dermatitis. Jan- Feb 2020;31(1):4-12. https://journals.lww.com/dermatitis/Fulltext/2020/01000/ Isobornyl_Acrylate.2.aspx . 7.Hagvall L, Bruze M, Engfeldt M, et al. Contact allergy to oxidized geraniol among Swedish dermatitis patients-A multicentre study by the Swedish Contact Dermatitis Research Group. Contact Dermatitis. Oct 2018;79(4):232-238. https://onlinelibrary. wiley.com/doi/abs/10.1111/cod.13047 .
Task force office
New task force bylaws : you need to know
“ A task force (TF) is defined as a group of specialists who bring together their skills and expertise to enable EADV to influence and advance specific fields of scientific, clinical and educational relevance, to dermatology and venereology. Each task force is concerned with a specific area of scientific, clinical or educational relevance. Task forces are internal to EADV and can be considered as centres of excellence . ”
EADV task forces do superb work . They are considered centres of excellence within EADV and make a substantial contribution to the Academy’s pursuit of our mission, exerting influence on relevant topics and promoting the image and prestige of EADV. Many task forces have produced guidelines, published reviews and surveys, organised courses and webinars and more. Last year, a number contributed to the creation of the COVID-19 Corner . Some task forces have become less active over the years and a boost was needed to enhance their productivity and stimulate the engagement of members.
EADV leadership therefore decided to update task force guidelines and introduce new features to help optimise internal functioning, improve interaction and cooperation and facilitate their management. Having been approved at the last Board meeting, the new task force bylaws are now in place. They are the result of the input of many EADV players: the task forces themselves expressed opinions and suggestions through an extensive survey and feedback was also received from the Executive Committee and the Board. Not to forget a final revision by the Statutes and Development Committee. • Mentorship has been introduced, meaning that junior members can become part of a task force • Good geographical representation among members is requested. In the near future, the four European regions (Northern, Southern, Eastern, Western) need to be represented within each task force (similarly in the composition of the the Scientific Programming Committee (SPC)) • An election process for task force leadership positions has been included • All task force members are expected to contribute to the work of the group. Task forces have full responsibility for the internal peer-reviewed material they release The task force office will work closely by the side of all task forces, helping Key insights include:
EADV TASK FORCES BYLAWS
*** Bylaws of the Board Section 5.4. “Task Forces”
Contents Task Force Definition....................................................................................................2 Purpose of Task Forces.................................................................................................2 Function and Role of Task Forces .................................................................................2 Establishing a Task Force..............................................................................................3 Task Force Leadership..................................................................................................4 Task Force Membership ...............................................................................................5 Task Force Facilitator ...................................................................................................6 Evaluation of Task Force Productivity...........................................................................7 Task Force and Task Force Member Responsibility and Liability ..................................7 Administrative Regulations ..........................................................................................8
increase their visibility. They are welcome to be actively involved in Academy life, for example by • Submitting articles to EADV News on activities and achievements • Publishing guidance/experiences regarding the COVID-19 pandemic (see COVID-19 Corner) • Supporting the SPC by proposing suggestions for upcoming congresses. It was also proposed to include a session with “Task Force Highlights” starting from 2022. All task forces approved in 2016 ended their four-year term in 2020 . They have been invited to submit their annual report, announce their wish for renewal and update their leadership and
• Melanoma • Mycology
membership list. Last but not least, please be aware that you can contact the task force office at any time. If you have a question or request, we will answer it as soon as possible and do our best to help. l
Christa De Cuyper, MD Task Force Facilitator Marina Binarelli Task Force Office Coordinator
• Pruritus • Psoriasis • Psychodermatology • Quality of life and patient outcomes • Sexually transmitted infections • Skin ageing • Skin diseases in pregnancy • Skin in organ transplant recipients • Tattoos and body art • Teledermatology • Tropical dermatology • Urticaria / angioedema • Vasculitis and vasculopathy • Vitiligo and pigmentary disorders • Wound healing
Call for new task forces We are committed to establishing further task forces as there are still many relevant topics to be covered by expert groups which could act as liaisons and provide added value to EADV and our members. These could include medical care inequalities, pharmaceutical strategies, etc. In 2020, we welcomed our 33 rd task force with a focus on tattoos and body art. Dermatologists often have to deal with questions from patients, healthcare practitioners and even body art practitioners about the safety of tattoos and piercing, and there is a need for reliable guidelines for the management of complications. The task force intends to prepare leaflets with recommendations for the general public and to develop a strategy for the management of tattoo complications. If you are interested in joining an existing task force , please contact the task force chair directly with your motivation and credentials. If you or your colleagues are interested in creating a new task force , please contact us , we will be happy to provide you with all the information you need, including the application form.
Skin Diseases in Pregnancy Task Force
Task force mentorship : a much valued initiative
Dr Samantha Vaughan Jones
Mentorship is a significant asset that can impact and shape the paths of next- generation dermatologists . The Skin Diseases in Pregnancy Task Force has been the pioneer in mentorship.
“ In 2007, we set up the EADV Pregnancy Task Force in Vienna, Austria, chaired by Dr Gudula Kirtschig. This provided a great new opportunity for European members with an interest in pregnancy dermatoses to share their experiences, encourage trainees and discuss topics of interest for research, publication and presentation at the annual EADV Congress. In 2016, I was appointed chair. In 2018, Dr Linda Martin (Australia) and I organised the inaugural EADV fostering course on pregnancy dermatology in Dubrovnik, Croatia. It was very well attended by trainees from all over Europe. At this course, I met three British trainees who I contacted on my return to the UK to see if they wished to develop their interest further. One, Ella McNulty-Brown, was keen to become a consultant and set up her own pregnancy clinic.
Our next EADV fostering course took place in September 2019 in Bratislava, Slovakia, with a larger number of delegates, including some consultants. It proved very popular; we had 100 applicants for just 25 places. On the final day, each delegate presented an interesting case of a pregnancy dermatosis they had seen. A prize was awarded for the best case presentation. Dr Iveta Gyliene (Lithuania) won the prize for an excellent case of restrictive dermopathy in pregnancy. At the 2019 EAVD Congress in Madrid, Spain, Dr Christa de Cuyper contacted me to discuss the Nurse Day to be held in Vienna, Austria, the following year, as 2020 was to be the Year of the Nurse and Midwife, to celebrate the 200 th anniversary of the birth of Florence Nightingale. As the proposed programme would cover pregnancy and paediatric dermatology, we planned several workshops on pregnancy- related dermatology, with relevance to mothers and babies, as well as to healthcare professionals. At this stage, I thought this would be a great opportunity for trainees to develop their presentation skills and gain experience of presenting at an international meeting by presenting at the Nurse Day. Three trainees offered to give presentations on various relevant topics. Due to the COVID-19 pandemic, the EADV Congress
“ Training and mentoring young colleagues is a two- way process: whilst helping them develop skills and gain experience, you pick up good ideas and feedback on how to improve your dermatology service. ”